Profile

Procarta Biosystems

Procarta Biosystems is a spin-out from one of Europe’s leading microbiology departments at the John Innes Centre. The company, formed in early 2008, is investigating a novel approach to counter antibiotic resistance and defeat infectious diseases using a DNA decoy technique, which aims to restore antibiotic efficacy against resistant superdrugs, such as methicillin-resistent Staphylococcus aureus (MRSA) and vancomycin-resistant Entercoccus (VRE).

Accessing the skills in the John Innes Centre, Procarta is also able to offer a contract research service creating and improving Streptomyces strains for heterologous production.

Status current

Associated Fund UK Innovation & Science Seed Fund

Sector Medical / Biotechnology

Website www.procartabio.com

Associated Team Members

Relevant News

Procarta receives carb-x award of up to $9.2 million

  FOR DEVELOPMENT OF NEW CLASS OF ANTIBIOTICS TO COMBAT LIFE-THREATENING DRUG-RESISTANT PATHOGENS Stevenage, UK,…

read more

University of East Anglia given multi-million-pound funding boost to combat...

Procarta Biosystems founder Prof Michael McArthur, from UEA's Norwich Medical School, said: "Our aim...

read more

'Breakthrough' drugs discovered in quest to solve antimicrobial resistance

The scientists from Procarta Biosystems, a company based at the University of East Anglia's...

read more

UK biotech bags €1.5m grant for new antibiotic class

Procarta Biosystems has picked up €1.5m in funding to help develop a new antibiotic...

read more

More Companies in Medical / Biotechnology